Drug lookup | Fillwise

Ach-Olmesartan · DIN 02456311 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ach-Olmesartan · DIN 02456311 Manufacturer: Accord Healthcare Inc.; listing date 2020-08-28 Health Canada: Marketed since 2020-05-06 · brand ACH-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Ach-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94319 · Verify on the e-Formulary ↗ (DIN 02456311)

Source record

DIN 02456311: Ach-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id ACH Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456311 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94319

Interchangeable products

Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: resolved shortage (ended 2026-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456311

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Olmesartan · DIN 02443864 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Olmesartan · DIN 02443864 Manufacturer: Auro Pharma Inc.; listing date 2017-06-29 Health Canada: Marketed since 2017-05-01 · brand AURO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92863 · Verify on the e-Formulary ↗ (DIN 02443864)

Source record

DIN 02443864: Auro-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id AUR Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443864 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92863

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: resolved shortage (ended 2024-10-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443864

Shortage record checked 2026-09-13T08:10:21.292534+00:00

GLN-Olmesartan · DIN 02469812 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

GLN-Olmesartan · DIN 02469812 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2020-12-18 Health Canada: Marketed since 2019-03-05 · brand GLN-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

GLN-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95870 · Verify on the e-Formulary ↗ (DIN 02469812)

Source record

DIN 02469812: GLN-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id GLP Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469812 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95870

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: resolved shortage (ended 2026-04-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02469812

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Olmesartan · DIN 02461641 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Olmesartan · DIN 02461641 Manufacturer: Jamp Pharma Corporation; listing date 2017-06-29 Health Canada: Marketed since 2021-10-28 · brand JAMP OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94931 · Verify on the e-Formulary ↗ (DIN 02461641)

Source record

DIN 02461641: Jamp-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id JPC Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461641 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94931

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: resolved shortage (ended 2025-03-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461641

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olmesartan · DIN 02499258 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olmesartan · DIN 02499258 Manufacturer: Nora Pharma; listing date 2020-12-18 Health Canada: Marketed since 2020-11-04 · brand NRA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98899 · Verify on the e-Formulary ↗ (DIN 02499258)

Source record

DIN 02499258: NRA-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id NRA Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02499258 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98899

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: resolved shortage (ended 2026-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02499258

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmesartan · DIN 02481057 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olmesartan · DIN 02481057 Manufacturer: Sanis Health Inc.; listing date 2020-10-30 Health Canada: Marketed since 2020-02-21 · brand OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97140 · Verify on the e-Formulary ↗ (DIN 02481057)

Source record

DIN 02481057: Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481057 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97140

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: anticipated shortage (last updated 2026-08-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481057

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmetec · DIN 02318660 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Olmetec · DIN 02318660 Manufacturer: Organon Canada Inc.; listing date 2010-04-23 Health Canada: Marketed since 2023-08-03 · brand OLMETEC · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80414 · Verify on the e-Formulary ↗ (DIN 02318660)

Source record

DIN 02318660: Olmetec Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id OCI Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.3993; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02318660 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80414

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: resolved shortage (ended 2023-08-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02318660

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Olmesartan · DIN 02461307 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Olmesartan · DIN 02461307 Manufacturer: Pharmascience Inc.; listing date 2017-07-31 Health Canada: Marketed since 2017-06-02 · brand PMS-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94881 · Verify on the e-Formulary ↗ (DIN 02461307)

Source record

DIN 02461307: PMS-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id PMS Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461307 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94881

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: discontinued (2021-11-15, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461307

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Olmesartan · DIN 02443414 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Olmesartan · DIN 02443414 Manufacturer: Sandoz Canada Inc.; listing date 2017-06-29 Health Canada: Marketed since 2017-05-01 · brand SANDOZ OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92810 · Verify on the e-Formulary ↗ (DIN 02443414)

Source record

DIN 02443414: Sandoz Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id SDZ Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443414 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92810

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: resolved shortage (ended 2026-04-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443414

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Olmesartan · DIN 02442191 · 20mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Olmesartan · DIN 02442191 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2023-03-10 · brand TEVA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92655 · Verify on the e-Formulary ↗ (DIN 02442191)

Source record

DIN 02442191: Teva-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442191 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92655

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Apo-Olmesartan · DIN 02453452 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019

Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442191

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ach-Olmesartan · DIN 02456338 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Ach-Olmesartan · DIN 02456338 Manufacturer: Accord Healthcare Inc.; listing date 2020-08-28 Health Canada: Marketed since 2020-05-06 · brand ACH-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Accord healthcare inc · schedule Prescription

Check this DIN again · Health Canada product record

Ach-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94320 · Verify on the e-Formulary ↗ (DIN 02456338)

Source record

DIN 02456338: Ach-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id ACH Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02456338 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94320

Interchangeable products

Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2026-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02456338

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Olmesartan · DIN 02443872 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Olmesartan · DIN 02443872 Manufacturer: Auro Pharma Inc.; listing date 2017-06-29 Health Canada: Marketed since 2017-05-01 · brand AURO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92864 · Verify on the e-Formulary ↗ (DIN 02443872)

Source record

DIN 02443872: Auro-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id AUR Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443872 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92864

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: discontinued (2023-11-21, reported by AURO PHARMA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443872

Shortage record checked 2026-09-13T08:10:21.292534+00:00

GLN-Olmesartan · DIN 02469820 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

GLN-Olmesartan · DIN 02469820 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2020-12-18 Health Canada: Marketed since 2019-03-05 · brand GLN-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Glenmark pharmaceuticals canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

GLN-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95871 · Verify on the e-Formulary ↗ (DIN 02469820)

Source record

DIN 02469820: GLN-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id GLP Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02469820 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95871

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2026-07-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02469820

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Olmesartan · DIN 02461668 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp-Olmesartan · DIN 02461668 Manufacturer: Jamp Pharma Corporation; listing date 2017-06-29 Health Canada: Marketed since 2021-10-28 · brand JAMP OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94932 · Verify on the e-Formulary ↗ (DIN 02461668)

Source record

DIN 02461668: Jamp-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id JPC Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461668 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94932

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2023-03-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461668

Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Olmesartan · DIN 02499266 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

NRA-Olmesartan · DIN 02499266 Manufacturer: Nora Pharma; listing date 2020-12-18 Health Canada: Marketed since 2020-11-04 · brand NRA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Nora pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

NRA-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98900 · Verify on the e-Formulary ↗ (DIN 02499266)

Source record

DIN 02499266: NRA-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id NRA Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02499266 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98900

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2026-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02499266

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmesartan · DIN 02481065 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Olmesartan · DIN 02481065 Manufacturer: Sanis Health Inc.; listing date 2020-10-30 Health Canada: Marketed since 2020-02-21 · brand OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97141 · Verify on the e-Formulary ↗ (DIN 02481065)

Source record

DIN 02481065: Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id SAI Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02481065 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97141

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2025-11-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02481065

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Olmetec · DIN 02318679 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

1 brand, same coverage

Olmetec · DIN 02318679 Manufacturer: Organon Canada Inc.; listing date 2010-04-23 Health Canada: Marketed since 2023-04-13 · brand OLMETEC · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Organon canada inc. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80415 · Verify on the e-Formulary ↗ (DIN 02318679)

Source record

DIN 02318679: Olmetec Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id OCI Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.3993; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02318679 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80415

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2020-09-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02318679

Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Olmesartan · DIN 02461315 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

PMS-Olmesartan · DIN 02461315 Manufacturer: Pharmascience Inc.; listing date 2017-07-31 Health Canada: Marketed since 2017-06-02 · brand PMS-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Pharmascience inc · schedule Prescription

Check this DIN again · Health Canada product record

PMS-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94882 · Verify on the e-Formulary ↗ (DIN 02461315)

Source record

DIN 02461315: PMS-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id PMS Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461315 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94882

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2026-04-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461315

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Olmesartan · DIN 02443422 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Sandoz Olmesartan · DIN 02443422 Manufacturer: Sandoz Canada Inc.; listing date 2017-06-29 Health Canada: Marketed since 2017-05-01 · brand SANDOZ OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Sandoz canada incorporated · schedule Prescription

Check this DIN again · Health Canada product record

Sandoz Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92811 · Verify on the e-Formulary ↗ (DIN 02443422)

Source record

DIN 02443422: Sandoz Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id SDZ Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443422 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92811

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: resolved shortage (ended 2026-05-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443422

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Olmesartan · DIN 02442205 · 40mg · tablet

General benefitMarketed · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Olmesartan · DIN 02442205 Manufacturer: Teva Canada Limited; listing date 2017-06-29 Health Canada: Marketed since 2023-03-10 · brand TEVA-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92656 · Verify on the e-Formulary ↗ (DIN 02442205)

Source record

DIN 02442205: Teva-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id TEV Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442205 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92656

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Apo-Olmesartan · DIN 02453460 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019

Shortage status: discontinued (2025-04-07, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02442205

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Olmesartan · DIN 02453452 · 20mg · tablet

General benefitDormant since 2025-05-16 · checked 2026-09-02 · What does dormant mean?

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Olmesartan · DIN 02453452 Manufacturer: Apotex Inc.; listing date 2017-06-29 Health Canada: Dormant since 2025-05-16 · brand APO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 20 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94000 · Verify on the e-Formulary ↗ (DIN 02453452)

Source record

DIN 02453452: Apo-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800284; group id 340; item number 0770; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453452 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94000

Interchangeable products

Ach-Olmesartan · DIN 02456311 · $0.3019 Auro-Olmesartan · DIN 02443864 · $0.3019 GLN-Olmesartan · DIN 02469812 · $0.3019 Jamp-Olmesartan · DIN 02461641 · $0.3019 NRA-Olmesartan · DIN 02499258 · $0.3019 Olmesartan · DIN 02481057 · $0.3019 Olmetec · DIN 02318660 · $0.3019 PMS-Olmesartan · DIN 02461307 · $0.3019 Sandoz Olmesartan · DIN 02443414 · $0.3019 Teva-Olmesartan · DIN 02442191 · $0.3019

Shortage status: active shortage (reported 2024-05-07, last updated 2024-05-10) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453452

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2025-05-16 — choose a marketed DIN from the same-category list.

Apo-Olmesartan · DIN 02453460 · 40mg · tablet

General benefitDormant since 2025-11-07 · checked 2026-09-02

Write on scriptno code needed

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Olmesartan · DIN 02453460 Manufacturer: Apotex Inc.; listing date 2017-06-29 Health Canada: Dormant since 2025-11-07 · brand APO-OLMESARTAN · ATC C09CA08 OLMESARTAN MEDOXOMIL · form Tablet · route Oral · ingredients OLMESARTAN MEDOXOMIL 40 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Olmesartan: Formulary list price $0.3019/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.3019 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94001 · Verify on the e-Formulary ↗ (DIN 02453460)

Source record

DIN 02453460: Apo-Olmesartan Raw flags: chronicUseMed=Y, sec3=Y Item: 240800285; group id 340; item number 0771; lccId None; manufacturer id APX Source form: Tab; strength: 40mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.3019; ministry $0.3019 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453460 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94001

Interchangeable products

Ach-Olmesartan · DIN 02456338 · $0.3019 Auro-Olmesartan · DIN 02443872 · $0.3019 GLN-Olmesartan · DIN 02469820 · $0.3019 Jamp-Olmesartan · DIN 02461668 · $0.3019 NRA-Olmesartan · DIN 02499266 · $0.3019 Olmesartan · DIN 02481065 · $0.3019 Olmetec · DIN 02318679 · $0.3019 PMS-Olmesartan · DIN 02461315 · $0.3019 Sandoz Olmesartan · DIN 02443422 · $0.3019 Teva-Olmesartan · DIN 02442205 · $0.3019

Shortage status: active shortage (reported 2024-11-12, last updated 2024-11-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02453460

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Health Canada lists this DIN as Dormant since 2025-11-07 — choose a marketed DIN from the same-category list.

OLMESARTAN MEDOXOMIL

Ach-Olmesartan · DIN 02456311 · 20mg · tablet

Auro-Olmesartan · DIN 02443864 · 20mg · tablet

GLN-Olmesartan · DIN 02469812 · 20mg · tablet

Jamp-Olmesartan · DIN 02461641 · 20mg · tablet

NRA-Olmesartan · DIN 02499258 · 20mg · tablet

Olmesartan · DIN 02481057 · 20mg · tablet

Olmetec · DIN 02318660 · 20mg · tablet

PMS-Olmesartan · DIN 02461307 · 20mg · tablet

Sandoz Olmesartan · DIN 02443414 · 20mg · tablet

Teva-Olmesartan · DIN 02442191 · 20mg · tablet

Ach-Olmesartan · DIN 02456338 · 40mg · tablet

Auro-Olmesartan · DIN 02443872 · 40mg · tablet

GLN-Olmesartan · DIN 02469820 · 40mg · tablet

Jamp-Olmesartan · DIN 02461668 · 40mg · tablet

NRA-Olmesartan · DIN 02499266 · 40mg · tablet

Olmesartan · DIN 02481065 · 40mg · tablet

Olmetec · DIN 02318679 · 40mg · tablet

PMS-Olmesartan · DIN 02461315 · 40mg · tablet

Sandoz Olmesartan · DIN 02443422 · 40mg · tablet

Teva-Olmesartan · DIN 02442205 · 40mg · tablet

Apo-Olmesartan · DIN 02453452 · 20mg · tablet

Apo-Olmesartan · DIN 02453460 · 40mg · tablet

OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE

Ach-Olmesartan HCTZ · DIN 02468948 · 20mg & 12.5mg · tablet

Act Olmesartan HCT · DIN 02443112 · 20mg & 12.5mg · tablet

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Availability